Verastem (VSTM) Competitors $8.94 -0.06 (-0.67%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$9.07 +0.13 (+1.45%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. CLDX, MNKD, BCRX, NVAX, INVA, OPK, DVAX, ZBIO, GERN, and MYGNShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors Celldex Therapeutics MannKind BioCryst Pharmaceuticals Novavax Innoviva OPKO Health Dynavax Technologies Zenas BioPharma Geron Myriad Genetics Celldex Therapeutics (NASDAQ:CLDX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Which has more volatility and risk, CLDX or VSTM? Celldex Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CLDX or VSTM? 88.4% of Verastem shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by company insiders. Comparatively, 2.1% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, CLDX or VSTM? Verastem has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M257.69-$157.86M-$3.01-9.05Verastem$2.14M257.47-$130.64M-$3.28-2.73 Is CLDX or VSTM more profitable? Verastem has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -3,446.88%. Verastem's return on equity of 0.00% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-3,446.88% -27.61% -26.20% Verastem N/A N/A -119.85% Do analysts recommend CLDX or VSTM? Celldex Therapeutics currently has a consensus target price of $46.13, suggesting a potential upside of 69.33%. Verastem has a consensus target price of $13.29, suggesting a potential upside of 48.61%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Verastem 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media prefer CLDX or VSTM? In the previous week, Verastem had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Verastem and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.53 beat Verastem's score of 0.26 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCelldex Therapeutics and Verastem tied by winning 8 of the 16 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$553.91M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-2.7321.5785.4827.61Price / Sales257.47271.42535.60201.12Price / CashN/A47.1237.9261.55Price / Book-13.7510.1412.976.76Net Income-$130.64M-$52.31M$3.30B$275.88M7 Day Performance-0.56%5.14%4.35%2.81%1 Month Performance-9.88%14.68%9.50%9.24%1 Year Performance198.00%30.98%84.38%35.42% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem2.9585 of 5 stars$8.94-0.7%$13.29+48.6%+206.2%$553.91M$2.14M-2.7350Analyst ForecastCLDXCelldex Therapeutics2.1433 of 5 stars$26.19+0.2%$46.13+76.1%-10.8%$1.74B$7.02M-8.70150Positive NewsAnalyst ForecastMNKDMannKind4.0373 of 5 stars$5.39-2.5%$11.17+107.2%-15.8%$1.70B$285.50M49.00400Positive NewsAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.1298 of 5 stars$7.55-1.0%$16.70+121.2%+1.1%$1.60B$450.71M-41.94530News CoverageAnalyst UpgradeNVAXNovavax4.3129 of 5 stars$8.57+0.2%$14.29+66.7%-31.7%$1.39B$682.16M3.761,990Analyst ForecastINVAInnoviva4.7717 of 5 stars$19.03+0.9%$42.75+124.6%-12.4%$1.19B$358.71M61.39100Analyst ForecastGap DownOPKOPKO Health4.2782 of 5 stars$1.47+1.4%$2.63+78.6%+5.4%$1.15B$713.10M-5.882,997Analyst ForecastDVAXDynavax Technologies4.5227 of 5 stars$9.66-1.2%$24.33+151.9%-4.2%$1.15B$277.25M-21.00350Positive NewsAnalyst ForecastZBIOZenas BioPharma1.585 of 5 stars$20.57+2.4%$36.67+78.3%N/A$846M$5M-5.79N/ATrending NewsAnalyst ForecastGap UpGERNGeron2.7787 of 5 stars$1.31+1.6%$3.79+189.0%-67.7%$823.04M$76.99M-10.0870News CoverageAnalyst ForecastMYGNMyriad Genetics3.9158 of 5 stars$7.24-6.0%$12.45+72.0%-70.6%$716.44M$837.60M-1.692,700 Related Companies and Tools Related Companies Celldex Therapeutics Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Geron Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
